<DOC>
	<DOCNO>NCT01099930</DOCNO>
	<brief_summary>Multiple sclerosis autoimmune disease . We study whether high dose chemotherapy autologous stem cell transplant replace autoreactive immune system reduce clinical inflammatory disease central nervous system ( CNS ) . A second goal examine whether long-term stabilization improvement disability score inflammatory disease control .</brief_summary>
	<brief_title>Autologous Stem Cell Transplant Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Age 18 50 year The diagnosis active multiple sclerosis relapse progression sustain accumulated impairment , make neurologist expert field Patient consider high risk progression EDSS Cerebellar Functional score great equal 3 OR EDSS Pyramidal Functional score great equal 3 EDSS great equal 3 less equal 6 Evidence current disease activity Evidence progression continue relapse worsen MRI least one year therapy interferonB1 , glatiramer acetate , Mitoxantrone , conventional dose immunosuppressive drug therapy If patient previously receive cytotoxic agent ( Mitoxantrone , Cyclophosphamide etc . ) must normal bone marrow morphology cytogenetics consider eligible study MRI brain scan satisfies MRI criterion Paty Fazekas diagnosis multiple sclerosis No evidence hepatic inflammation fibrosis Patients primary progressive multiple sclerosis Patients cardiac , renal , pulmonary , hepatic organ impairment would limit ability receive dose intensive immunosuppressive therapy include high dose chemotherapy ASCT Patient active chronic infection Patients seropositive HIV1 , HIV2 , Hepatitis B Surface Antigen , Hepatitis C Patients previous history malignancy basal cell carcinoma skin carcinoma situ remission one year Patients whose life expectancy severely limit another comorbid illness Patients evidence myelodysplasia nonautoimmune cytopenia Patients receive cytotoxic agent within one month enrol study Pregnancy risk pregnancy . This include patient unwilling practice active contraception time chemotherapy Patients hypersensitivity rabbit proteins Patients unable give write informed consent accordance research ethic board guideline Patients previous exposure natalizumab alemtuzumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>immunoablation</keyword>
	<keyword>stem cell transplantation</keyword>
</DOC>